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Pulmonary mucin-producing adenocarcinomas may be indistinguishable on conventional 
histology from a metastasis, as TTF-1 expression often is lacking and KRAS mutations are 
widely present even in extra-pulmonary sites. Few data have been reported on the 
diagnostic role of napsin-A and EGFR and ALK gene alterations in this challenging 
differential diagnosis. Seventy-seven surgically resected cases, including 53 primary and 
24 metastatic tumors from different sites, were evaluated for Napsin-A, TTF-1 and ALK by 
immunohistochemistry and for EGFR mutations by direct sequencing. Overall, napsin-A 
expression in primary lung mucin-producing adenocarcinomas was 36% (8% mucinous, 
17% colloid, 87.5% solid, and 100% signet ring cell) and TTF-1 expression reached an 
overall figure of 42% (12.5% mucinous, 33% colloid, 87.5% solid, and 100% signet ring 
cell). Metastatic mucinous adenocarcinomas did not react with napsin-A or with TTF-1. All 
primary and metastatic tumors lacked EGFR mutations, while a single case of signet ring 
cell lung adenocarcinoma showed ALK expression and rearrangement at FISH analysis. 
Napsin-A has a lower sensitivity compared to TTF-1 in primary mucin-producing 
adenocarcinomas of the lung. However, both antibodies have an absolute specificity, 
being always negative in metastatic mucinous adenocarcinomas. EGFR mutations and 
ALK translocation or expression are exceedingly rare in mucin-producing 
adenocarcinomas of the lung, resulting unnecessary as diagnostic tool in this setting. 
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In the lung, the differential diagnosis between primary and metastatic adenocarcinomas 
may be challenging, particularly when dealing with mucin-producing adenocarcinomas. In 
fact, the morphologic features of pulmonary (mucinous, colloid, signet-ring cell, solid with 
mucin) and extrapulmonary mucin-producing adenocarcinomas, particularly from 
pancreato-biliary tract, are frequently overlapping1. Immunohistochemical studies with 
some specific markers of lung primary, namely thyroid transcription factor-1 (TTF-1), 
surfactant apoproteins and cytokeratin (CK) 7, and of extrapulmonary origin, as caudal-
related homeobox gene (CDX2) and CK20, are generally helpful2,3. Nevertheless, lack of 
pulmonary markers and aberrant expression of CDX2 and CK20 have been well 
demonstrated in some mucin-producing adenocarcinomas of the lung4-13. In addition, 
metastatic adenocarcinomas may grow along alveolar structures in a lepidic pattern, then 
closely mimicking primary lung adenocarcinomas1.  
While TTF-1 is still considered the most specific marker in differentiating lung primary 
versus metastatic adenocarcinomas14, some disturbing staining have been reported in 
several extrapulmonary adenocarcinomas, mainly from gynaecologic tract15,16, and 
different specificity have been observed using different clones recognizing TTF-1.17 
Napsin-A is a relatively novel marker of lung and renal primary, consisting of an aspartic 
proteinase homologous to polypeptide TA02 involved in the maturation of surfactant and 
expressed in normal type II pneumocytes and intra-alveolar macrophages because of 
surfactant phagocytosis.18-21 To date, only Wu et al22 have investigated the role of napsin-
A in mucin-producing adenocarcinomas of the lung and extrapulmonary mucinous 
adenocarcinomas of different sites, reporting high specificity but low sensitivity of Napsin-A 
expression in primary mucin-producing adenocarcinomas of the lung. 
In the current study, we compared the value of TTF-1 and napsin-A in a series of 77 
surgically resected lung primary (53 cases) and metastatic (24 cases) mucin-producing 
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adenocarcinomas. Genetic alterations involving epidermal growth factor receptor (EGFR) 
and anaplastic lymphoma kinase (ALK) have a critical value in predicting clinical response 
to targeted molecular therapies with specific inhibitors,23-25 but are also strikingly restricted 
to lung adenocarcinomas. Thus, molecular investigation of EGFR mutations by direct 
sequencing method and demonstration of ALK aberrant expression have been tested in all 
tumors of our series as a possible alternative diagnostic tool in discriminating primary 
versus metastatic mucinous adenocarcinomas. 
 
MATERIALS AND METHODS 
Case series. The files of the Operative Unit of Pathologic Anatomy of the Azienda 
Arcispedale S. Maria Nuova of Reggio Emilia, the University Hospital Policlinico of 
Modena and the Unit of Pathologic Anatomy of the University Hospital of 
Torino/Orbassano were searched for cases of pulmonary primary and metastatic mucin-
producing adenocarcinomas diagnosed from 1991 to 2011. Overall, 53 primary lung and 
24 metastatic tumors were collected. All the cases consisted of surgical specimens (19 
wedge resections and 58 pulmonary lobectomies). Surgical samples were processed 
according to conventional protocol26 and the tissue was routinely fixed in 10% buffered 
formalin and paraffin-embedded. The histologic classification was based on review of all 
hematoxylin and eosin-stained sections of the primary tumor (mean, 3 slides for each 
tumor; range, 2–6 slides). Slide review was performed by two pathologists (GR, AC) using 
a multi-headed microscope. Primary lung adenocarcinomas were classified according to 
the 2004 World Health Organization (WHO) criteria27 and the International Association for 
the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European 
Respiratory Society (ERS) classification.28  
 
Rossi G et al 
5 
 
Immunohistochemistry. For immunohistochemical analysis, the following antibodies 
were used: TTF-1 (clone 8G7G3 ⁄ 1, 1:500 dilution; Ventana, Tucson, AZ, USA) and 
napsin-A (polyclonal; Ventana; prediluted) with an automated immunostainer (BenchMark; 
Ventana), as reported previously.29 In each case, 4-μm-thick sections obtained from a 
representative block were air-dried overnight at 37°C, then deparaffinized in xylene and 
rehydrated through a decreasing concentration of alcohol to water; 3-3-diaminobenzidine 
was used as the chromogene and Harris hematoxylin as the counterstain. Alveolar type II 
cells served as positive internal controls. Negative controls were included in each test by 
substituting the primary antibodies with nonimmune mouse IgG, at the same concentration 
as that of the relevant primary antibody. A tumor was considered positive if more than 10% 
of the neoplastic cells reacted, with a moderate (2+) or strong (3+) intensity, in the relevant 
subcellular localization (nuclear for TTF-1 and granular cytoplasmic for napsin-A). Clinical 
and radiologic data of patients were collected from pathologic reports, clinical charts, 
referring physicians, or directly from the patient’s families.  
 
Molecular analysis. Molecular analysis was performed by direct sequencing PCR as 
previously described.30 Briefly, 5-micron thick sections obtained from a representative 
paraffin-embedded block were deparaffinized by xylene, and tumor DNA was extracted 
using a manual microdissection method. Microdissected tumor cells were subjected to 
proteinase K treatment in a digestion buffer (50mM Tris [pH 8.5], 1 mM EDTA, 0.5% 
Tween 20) and then incubated ovenight at 37°C. PCR was performed in 10μL reaction mix 
containing 1.0μg DNA, 1μl of commercial PCR buffer (Applied Biosystem), 1.0-2.0mM 
MgCl2, 200μM of each dNTP, 25pmol of each primer, and 1.5 units of AmpliTaq gold 
polymerase (Applied Biosystem). PCR reaction was carried out on Uno II Thermoblock 
(Biometra, Gottingen, Germany). Initial denaturation at 94°C for 10 minutes was followed 
by 41 cycles, and a final extension step (7 minutes at 72°C). The cycles included 
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denaturation at 95°C for 1 minute, annealing at 55-65°C for 1 minute, and extension at 
72°C for 2 minutes. The amplified DNA was electrophoresed on 2% agarose gel for 1 hour 
at 110V. The amplification products were then purified using the Wizard SV Gel and PCR 
Clean-Up System (Promega) according to the manufacturer’s instructions and were 
sequenced in both directions on an ABIPrism 310 automatic sequencer (Applied 
Biosystems) using the Big Dye Terminator Kit. The data were analyzed with the 
Sequencing Analysis 5.2 Software (Applied Biosystem). The forward and reverse 
sequences of EGFR exons 18, 19, and 21 were analyzed. 
The presence of ALK alteration was preliminarily screened using the following 2 antibodies 
against ALK: clone ALK1 (Ventana, prediluted) and clone 5A4 (Novocastra, 1:50 dilution). 
In case of any expression of ALK (from 1+, weak to 3+, strong) further confirmation of ALK 
rearrangement was performed by fluorescent in situ hybridization (FISH) using dual color 
break-apart probes (Vysis, Abbott Molecular) according to conventional recommendations. 
A positive case was recorded when rearrangement for ALK was present in more than 15% 
of tumor cells considering broken-apart green/red signals and/or single red signals. 
 
Statistical analysis. Results were tested for significance using the Pearson’s chi-square 
test. Differences were considered significant at P values < 0.05. 
 
RESULTS 
Immunohistochemical results comparing the expression of napsin-A and TTF-1 are 
summarized in Table 1.  Napsin-A was expressed in 19 out of 53 mucin-producing 
adenocarcinomas of the lung (36%), including 2 out of 25 (8%) mucinous 
adenocarcinomas (formerly mucinous bronchioloalveolar carcinomas), all 8 
adenocarcinomas with signet ring features, 2 out of 12 (17%) colloid and 7 out of 8 
(87.5%) solid-type adenocarcinomas. Strong (3+) expression for napsin-A was mainly 
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observed in signet ring and solid-type adenocarcinomas, while a moderate (2+) staining 
characterized colloid and mucinous type adenocarcinomas (Figure 1).  
TTF-1 expression was observed in 22 out of 53 (41.5%) mucin-producing 
adenocarcinomas of the lung, in particular 3 out of 25 (12%) mucinous adenocarcinomas, 
all the 8 adenocarcinomas with signet ring features, 4 out of 12 (33%) colloid and 7 out of 
8 (87.5%) solid-type adenocarcinomas. 
Comparison of napsin-A and TTF-1 expression did not reveal discrepant results, but 3 
napsin-A negative cases (1 mucinous and 2 colloid) were immunoreactive for TTF-1.  No 
immunoreactivity for Napsin-A or TTF-1 was recorded in metastatic mucinous 
adenocarcinomas from colon, pancreas, breast, ovary and sinonasal tract. 
No EGFR mutations were disclosed in primary and metastatic tumors, while only 1 case of 
pulmonary adenocarcinoma featuring signet ring cells expressed ALK protein and showed 
ALK rearrangement upon FISH testing (Table 2). 
No significant differences were observed when comparing immunohistochemical results 




In the lung, histologic discrimination between primary and metastatic mucin-producing 
adenocarcinomas may be a formidable challenge on conventional stains, often requiring 
the use of immunomarkers. While the low sensitivity limits the role of TTF-1 in this 
differential diagnosis and the expression of intestinal differentiation markers (i.e., CK20 
and CDX2) is not an uncommon occurrence, only few data have been reported on the use 
of napsin-A or specific gene alterations of lung adenocarcinomas, namely EGFR mutations 
and ALK rearrangement, in this peculiar setting of differential diagnosis. 
Rossi G et al 
8 
 
Napsin-A is an aspartic proteinase acting in the maturation of surfactant recently and 
resulting a quite specific marker of adenocarcinomas taking origin from kidney and lung.31 
In primary pulmonary tumors, napsin-A is strictly expressed in 60% to 90% of 
adenocarcinomas, but never in squamous cell carcinomas and neuroendocrine tumors.32 A 
weak staining for napsin-A has been observed only in occasional tumors outside the lung 
and kidney.33 The specificity and sensitivity of napsin-A in discriminating adenocarcinoma 
lineage from other histotypes of non-small cell lung cancer (NSCLC) is considered akin to 
or slightly superior than that observed for TTF-1.31,32 Among pulmonary adenocarcinomas, 
mucin-producing variants have demonstrated the lowest rate of TTF-1 expression, then 
limiting the value of TTF-1 in discriminating primary pulmonary from metastatic mucinous 
adenocarcinomas.5,6,9,11,32 Napsin-A immunoreactivity in mucin-producing 
adenocarcinomas of the lung and other primary extrapulmonary mucinous 
adenocarcinomas (colorectum, breast, stomach, pancreas and ovary) has been recently 
analyzed by Wu et al.22 The authors found an overall sensitivity of 33% and 42% in primary 
lung mucin-producing adenocarcinomas for napsin-A and TTF-1, respectively. Some 
discrepancies between the two markers have been noted with an higher rate of TTF-1 
expression in solid, colloid and signet ring cell type.22 Other sporadic studies reported a 
weak immunoreactivity of napsin-A in mucinous adenocarcinoma (formerly 
bronchioloalveolar carcinoma, mucinous type) ranging from 0% to 86%.34,35 The results in 
the current study do not significantly differ from those reported by Wu et al22 with an overall 
higher rate of TTF-1 (42%) than napsin-A (36%) expression in mucin-producing 
adenocarcinomas of the lung. As highlighted previously22 discrepancies among different 
studies on this issue may be related to methodologies employed in performing 
immunostaining with different clones of napsin-A. In fact, Mukhopadhyay and 
Katzenstein36 recently demonstrated that monoclonal antibody recognizing napsin-A is 
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less sensitive, but more specific than polyclonal antiserum in discriminating lung origin of 
adenocarcinomas. 
In general, the low expression for napsin-A, as well as TTF-1, in some types (mucinous 
and colloid) of primary pulmonary mucin-producing adenocarcinomas limits their value in 
the distinction from metastatic mucin-producing adenocarcinomas. However, their 
specificity is 100% since all mucinous adenocarcinomas from other sites are entirely 
negative, both in the current paper and Wu’s et al work. 22  
Theoretically, also molecular investigations could have a role in this differential diagnosis. 
While identical KRAS mutations are widely identified in pulmonary and extrapulmonary 
mucin-producing adenocarcinomas,37 gene alterations involving EGFR and ALK seem to 
be much more restricted to primary adenocarcinomas of the lung.38 Whether previous 
studies30,39-41 have demonstrated that mucinous adenocarcinomas of the lung tend to be 
wild-type at EGFR mutational analysis, herein we observed that also the other variants of 
primary lung and metastatic mucin-producing adenocarcinomas do not harbor EGFR 
mutations. Several works have underlined the significant relationship between ALK 
rearrangement and signet ring cell pattern of lung adenocarcinomas,42-44 but no studies 
have explored ALK alterations along the spectrum of mucin-producing pulmonary 
adenocarcinomas and metastatic mucinous adenocarcinomas of different origin. In light of 
the significant correlation between immunohistochemistry and FISH methods in detecting 
ALK rearrangement,45-47 we originally screened all 77 cases with two different clones 
(ALK1 and 5A4) directed against ALK protein. Only one positive case (a pulmonary 
adenocarcinoma with signet ring cells) was detected, subsequently confirmed to harbor 
ALK rearrangement upon FISH testing. In this study, EGFR and ALK gene alterations 
were not detected in any case of metastatic mucinous extrapulmonary tumors. 
The low frequency of napsin-A (8%) and TTF-1 (12%) expression and the lack of 
alterations of genes specifically related to lung adenocarcinomas further confirm the 
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extreme difficulty in discriminating primary mucinous adenocarcinomas of the lung from 
metastatic mucinous adenocarcinomas, once clinicoradiologic and morphology have 
failed. Nevertheless, in other types of mucin-producing lung adenocarcinomas, namely 
colloid, signet ring cell and solid types, expression of napsin-A specifically identified the 
lung as the primary site of 61% cases, a figure overlapping to that observed with TTF-1 
(68%).  
Despite in our series napsin-A did not add further information in TTF-1 negative cases, as 
reported by Wu et al22 and Ye et al,48 the coordinated use of TTF-1 and Napsin-A in 
mucin-producing adenocarcinomas of the lung could cover a larger spectrum of tumors, 
somehow obviating to the low sensitivity when employing a single marker. 
In summary, mucin-producing adenocarcinomas of the lung represent several distinct 
tumor entities with different expression of napsin-A and TTF-1, possibly related to different 
derivation from lung structures.49 Napsin-A immunoreactivity is very limited in mucinous 
adenocarcinoma (8%), but is 17%, 87.5% and 100% in colloid, solid and signet ring cell 
types, respectively. No expression has been noted for both napsin-A and TTF-1 in 
metastatic mucinous adenocarcinoma from colon, pancreas, ovary, breast and sinonasal 
tract. Finally, genetic alterations of EGFR and ALK have no diagnostic role in 
discriminating pulmonary from extra-pulmonary metastatic mucin-producing 
adenocarcinomas, apart from occasional ALK-rearranged adenocarcinomas composed of 
signet ring cells.  
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Figure 1. Immunoreactivity for Napsin-A in mucinous (A), colloid (B), signet ring cell (C) 




TTF-1: thyroid transcription factor-1 
ALK: anaplastic lymphoma kinase 
Napsin-A: novel aspartic proteinase of the pepsin family A 
EGFR: epidermal growth factor receptor 
KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 


















Table 1. Distribution of Napsin A and TTF-1 expression among lung primary and 
metastatic mucin-producing adenocarcinomas 
 
       Napsin A   TTF-1 
         n/tot (%) 
 
Lung primary adenocarcinoma (n=53)       
- Mucinous (n=25)    2/25 (8)   3/25 (12) 
- Signet ring (n=8)    8/8 (100)   8/8 (100) 
- Colloid (n=12)    2/12 (17)   4/12 (33) 
- Solid (n=8)     7/8 (87.5)   7/8 (87.5)  
Overall     19/53 (36)   22/53 (41.5) 
 
Lung metastatic mucinous adenocarcinoma (n=24) 
 - Pancreas (n=6)    0/6    0/6   
 - Ovary (n= 3)    0/3    0/3 
 - Breast (n=2)    0/2    0/2 
 - Colon (n=11)    0/11    0/11 
 - Sinonasal tract (n=2)   0/2    0/2  
 Overall     0/24    0/24 
 








Table 2. Distribution of EGFR and ALK alterations among lung primary and 
metastatic mucin-producing adenocarcinomas 
 
        EGFR    ALK 
          n/tot (%) 
 
Lung primary adenocarcinoma (n=53)   
- Mucinous (n=25)     0/25    0/25  
- Signet ring (n=8)     0/8    1/8 (12.5) 
- Colloid (n=12)     0/12    0/12 
- Solid (n=8)      0/8    0/8 
 Overall      0/53    1/53 (1.8) 
 
Lung metastatic mucinous adenocarcinoma (n=24)  
 - Pancreas (n=6)     0/6    0/6 
 - Ovary (n= 3)     0/3    0/3 
 - Breast (n=2)     0/3    0/2 
 - Colon (n=11)     0/11    0/11 
 - Sinonasal tract (n=2)    0/2    0/2 
 Overall      0/24    0/24 
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Figure 1 
 
 
 
 
 
 
 
 
